Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Merck Foundation Fashion Awards 2023 Winners Announced to Acknowledge their Work to Empower Infertile Women and Support Girl ...

Merck CEO Robert Davis said on an earnings call that Gardasil inventory in China "remains elevated at above normal levels," noting that demand for the shot has not recovered to the level the ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

Shares of Merck are sliding in early trading after the ... to China at least through the middle of the year. Chairman and CEO Robert Davis told analysts the pause will help pare inventory and ...

Merck & Co Inc (MRK) reports robust sales growth driven by KEYTRUDA and WINREVAIR, while navigating GARDASIL demand issues in ...